Precision BioSciences Shows First Evidence Of CccDNA Elimination In Hepatitis B Patients; Stock Up

Precision BioSciences reported landmark clinical data from its ELIMINATE-B study showing, for the first time, that a therapeutic agent can directly eliminate and inactivate cccDNA, the root source of hepatitis B viral replication. The result is a meaningful scientific advance for the company’s HBV program and supports its platform validation. The news is likely supportive for DTIL shares, though the article does not provide efficacy percentages or regulatory milestones.

Analysis

Precision BioSciences reported landmark clinical data from its ELIMINATE-B study showing, for the first time, that a therapeutic agent can directly eliminate and inactivate cccDNA, the root source of hepatitis B viral replication. The result is a meaningful scientific advance for the company’s HBV program and supports its platform validation. The news is likely supportive for DTIL shares, though the article does not provide efficacy percentages or regulatory milestones.